HemeRetic
| Primary Site | Histology | Behavior | Schema Discriminator 1 | Year of Diagnosis |
|---|---|---|---|---|
| C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809 | 9591 | <Any value> | 1, 2 | <Any value> |
| C700-C729, C751-C753 | 9591 | 3 | 1, 2 | <Any value> |
| C000-C699, C739-C750, C754-C809 | 9724, 9727, 9740-9742, 9749, 9762-9809, 9811-9820, 9831-9920, 9931-9993 | <Any value> | <Any value> | <Any value> |
| C700-C729, C751-C753 | 9724, 9727, 9740-9742, 9762-9765, 9767-9809, 9811-9820, 9831-9920, 9931-9993 | 3 | <Any value> | <Any value> |
| C700-C729, C751-C753 | 9749, 9766 | 3 | <Any value> | 2018-2022 |
| C000-C699, C739-C750, C754-C809 | 9751, 9755-9759 | <Any value> | <Any value> | <Any value> |
| C000-C440, C442-C689, C691-C694, C698-C699, C739-C750, C754-C809 | 9930 | <Any value> | <Any value> | <Any value> |
| C700-C729, C751-C753 | 9930 | 3 | <Any value> | <Any value> |
Notes
9724, 9727, 9740-9742, 9749, 9762-9809, 9811-9820, 9831-9920, 9931-9993 * C700-C729, C751-C753 for 9749, 9766 (2018-2022 only) (See **Note 2**) C000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 1, 2 C000-C699, C739-C750, C754-C809: 9751, 9755-9759 C000-C440, C442-C689, C691-C694, C698-C809: 9930 **Note 1:** **Sources used in the development of this schema** * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 83 *Leukemia*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** * For the histologies and primary sites listed below, these have moved to the Brain, CNS Other, and Intracranial Gland schemas starting with 2023 diagnoses. * If you have one of these cases for 2018-2022, then this is the appropriate schema. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate schema * **9749, 9766** * **Brain**: C700, C710-C719 * **CNS Other**: C701, C709, C720-C725, C728-C729 * **Intracranial Gland**: C751-C753 **Note 3:** **Other EOD Schemas with the listed histologies** * **Brain**: 9751, 9755-9759 (C700, C710-C719) * **CNS Other**: 9751, 9755-9759 (C701, C709, C720-C725, C728-C729) * **Intracranial Gland**: 9751, 9755-9759 (C751-C753) * **Lymphoma**: 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809) * **Lymphoma Ocular Adnexa**: 9930 (C441, C690, C695-C696) **Note 4:** **Summary Stage** * Summary Stage is the only applicable staging system for this site/histology/schema. **Note 5:** **Histologies and Primary Sites** * See list of specific histologies below, effective for cases diagnosed 2010 and forward. * All primary sites (C000-C809) are included unless otherwise specified. **Note 6:** **Schema includes the preferred terms based on the 2024 WHO Classification of Tumours, Haematolymphoid tumors, 5th edition** * 9591 Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696) * 9724: Systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL) * 9727: Blastic plasmacytoid dendritic cell neoplasm (BPDC) * 9740: Mast cell sarcoma (MSC) * 9741: Systemic mastocytosis with an associated hematological neoplasm (SM-AHN) * 9742: Mast cell leukemia (MCL) * 9749: Erdheim-Chester disease (ECD) (2021+ only) (except C700-C729, C751-C753 for 1/1/2023+) * 9750: ALK-positive histiocytosis * 9751: Langerhans cell histiocytosis, disseminated (except C700-C729, C751-C753) * 9755: Histiocytic sarcoma (except C700-C729, C751-C753) * 9756: Langerhans cell sarcoma (LCS) (except C700-C729, C751-C753) * 9757: Interdigitating dendritic cell sarcoma (IDCS) (except C700-C729, C751-C753) * 9758: Follicular dendritic cell sarcoma (FDCS) (except C700-C729, C751-C753) * 9759: Fibroblastic reticular cell tumor (except C700-C729, C751-C753) * 9762: Heavy chain diseases, NOS (HCD) * 9766: Lymphomatoid granulomatosis (LyG) grade 3 (2021+ only) (except C700-C729, C751-C753 for 1/1/2023+) * 9800 Leukemia, NOS * 9801: Acute undifferentiated leukemia * 9805: Acute leukemia of ambiguous lineage with other defined genetic alterations * 9806: Mixed-phenotype acute leukemia (MPAL) with *BCR::ABL1* fusion * 9807: Mixed-phenotype acute leukemia (MPAL) with *KMT2A-rearranged* * 9808: Mixed -phenotype acute leukemia, B/myeloid, NOS * 9809: Mixed-phenotype acute leukemia (MPAL), T/myeloid, NOS * 9811: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL], NOS * 9812: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 fusion* * 9813: B lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *KMT2A rearrangement* * 9814: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *ETV6::RUNX1 fusion* * 9815: B-lymphoblastic leukemia/lymphoma with high hyperdiploidy (B-ALL/LBL with high hyperdiploidy) * 9816: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with hypodiploidy (Hypodiploid B-ALL/LBL) * 9817: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *IGH::IL3 fusion* * 9818: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *TCF3::PBX1* * 9819: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 like features* (BCR::ABL1-like B-ALL/LBL) (2021+ only) * 9820: Lymphoid leukemia, NOS * 9831: T-large granular lymphocytic leukemia (T-LGLL) * 9832: Prolymphocytic leukemia (PPL), NOS * 9833: Prolymphocytic leukemia, B-cell type (BLL) * 9834: T-cell prolymphocytic leukemia (T-PLL) * 9837: T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) * 9840: Acute erythroid leukemia (AEL) * 9860: Myeloid leukemia, NOS * 9861: Acute myeloid leukemia (AML), NOS * 9863: Chronic myeloid leukemia (CML), NOS * 9865: Acute myeloid leukemia with *DEK::NUP214 fusion* * 9866: Acute promyelocytic leukemia with *PML::RARA* fusion (APL with *PML::RARA*) * 9867: Acute myelomonocytic leukemia, NOS (AMML) * 9869: Acute myeloid leukemia with *MECOM rearrangement* * 9870: Acute basophilic leukemia * 9871: Acute myeloid leukemia with *CBFB::MYH11 fusion* * 9872: Acute myeloid leukemia, minimal differentiation * 9873: Acute myeloid leukemia without maturation * 9874: Acute myeloid leukemia with maturation * 9875: Chronic myeloid leukemia (CML), *BCR::ABL1 positive* * 9876: Myelodysplastic/myeloproliferative neoplasm with neutrophilia (MDS/MPN-N) * 9877: Acute myeloid leukemia with mutated *NPM1* (2021+ only) * 9878: Acute myeloid leukemia with *CEBPA mutation* (2021+ only) * 9879: Acute myeloid leukemia with mutated *RUNX1* (2021+ only) * 9891: Acute monocytic leukemia * 9895: Myelodysplasia-related acute myeloid leukemia (AML-MR) * 9896: Acute myeloid leukemia with *RUNX1::RUNX1T1* * 9897: Acute myeloid leukemia with *KMT2a rearrangement* * 9898: Myeloid leukemia associated with Down Syndrome (ML-DS) * 9910: Acute megakaryoblastic leukemia (AMKL) * 9911: Acute myeloid leukemia (megakaryoblastic) with *RBMI5::MRTFA* * 9912: Acute myeloid leukemia with *BCR::ABL1 fusion* (2021+ only) * 9920 Therapy-related myeloid neoplasms * 9930: Myeloid sarcoma (MS) (except C441, C690, C695-C696) * 9931: Acute panmyelosis with myelofibrosis (APMF) * 9940: Hairy cell leukemia (HCL) * 9945: Chronic myelomonocytic leukemia, NOS (CMML) * 9946: Juvenile myelomonocytic leukemia (JMML) * 9948: Aggressive NK-cell leukemia (ANKL) * 9950: Polycythemia vera (PV) * 9961: Primary myelofibrosis (PMF) * 9962: Essential thrombocythemia (ET) * 9963: Chronic neutrophilic leukemia (CNL) * 9964: Chronic eosinophilic leukemia (CEL) * 9965: Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement * 9966: Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement * 9967: Myeloid/lymphoid neoplasm with *FGFR1* rearrangement * 9968: Myeloid/lymphoid neoplasm with *JAK2* rearrangement (2021+ only) * 9971 Post-transplant lymphoproliferative disorder, NOS (PTLD, NOS) (2018-2020, 2025+) * *Note:* 9971 is /1 for 2021-2024, moved back to /3 for 1/1/2025+ * 9975: Myelodysplastic/myeloproliferative neoplasm, NOS, unclassifiable (MPN/MDS-U) * 9980: Myelodysplastic neoplasm with low blasts and single-lineage dysplasia (MDS-LB-SLD) * 9982: Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD) * 9983: Myelodysplastic neoplasm with increased blasts (MDS-IB) * 9985: Myelodysplastic neoplasm with low blasts, NOS (MDS-LB) * 9986: Myelodysplastic neoplasm with low blasts and 5q deletion (MDS-5q) * 9989: Myelodysplastic neoplasm, NOS * 9991: Refractory neutropenia (2018-2020 only, see code 9980/3 for 2021+) * 9992: Refractory thrombocytopenia (2018-2020 only, see code 9980/3 for 2021+) * 9993: Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (2021+)Data Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata |
|---|---|---|---|---|---|
| Year of Diagnosis | Yes |
NAACCR #390
dateOfDiagnosis |
None | ||
| Primary Site | Yes |
NAACCR #400
primarySite |
None | ||
| Histology | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | ||
| Behavior | Yes |
NAACCR #523
behaviorCodeIcdO3 |
None | ||
| Schema Discriminator 1 | Yes |
NAACCR #3926
schemaDiscriminator1 |
All | SSDI | |
| Age at Diagnosis | No |
NAACCR #230
ageAtDiagnosis |
None | ||
| Type of Reporting Source | No |
NAACCR #500
typeOfReportingSource |
None | ||
| Tumor Size Clinical | 999 | No |
NAACCR #752
tumorSizeClinical |
None | |
| Tumor Size Pathological | 999 | No |
NAACCR #754
tumorSizePathologic |
None | |
| Tumor Size Summary | 999 | No |
NAACCR #756
tumorSizeSummary |
None | |
| Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
| Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
| Neoadjuvant Therapy | 0 | No |
NAACCR #1632
neoadjuvantTherapy |
None | |
| Neoadjuvant Therapy – Clinical Response | 0 | No |
NAACCR #1633
neoadjuvTherapyClinicalResponse |
None | |
| Neoadjuvant Therapy – Treatment Effect | 0 | No |
NAACCR #1634
neoadjuvTherapyTreatmentEffect |
None | |
| EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
| EOD Regional Nodes | 888 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
| EOD Mets | 88 | Yes |
NAACCR #776
eodMets |
None | |
| SS2018 | No |
NAACCR #764
summaryStage2018 |
None | ||
| Grade Clinical | 8 | Yes |
NAACCR #3843
gradeClinical |
All | SSDI |
| Grade Pathological | 8 | Yes |
NAACCR #3844
gradePathological |
All | SSDI |
| Grade Post Therapy Clin (yc) | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI | |
| Grade Post Therapy Path (yp) | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI | |
| JAK2 | 8 | No |
NAACCR #3862
jak2 |
COC SEER |
SSDI |
Initial Context
Outputs
| Name | Default Value | Description | NAACCR Item | Metadata |
|---|---|---|---|---|
| Schema ID | 00830 |
NAACCR #3800
schemaId |
None | |
| Derived Version | {{ctx_alg_version}} | None | None | |
| Derived Summary Stage 2018 | 9 |
NAACCR #762
derivedSummaryStage2018 |
None | |
| Derived Summary Grade 2018 | <BLANK> |
NAACCR #1975
derivedSummaryGrade2018 |
None |